Welcome to our dedicated page for Aveanna Healthcare Holdings SEC filings (Ticker: AVAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aveanna Healthcare Holdings Inc. filings document the public-company disclosures of a home healthcare operator with pediatric and adult care services. Its 8-K reports cover operating and financial results, guidance updates, Regulation FD investor presentations, material-event disclosures, capital-structure matters, and material agreements tied to the company and its common stock.
Proxy and governance filings describe annual meeting matters, board composition, committee service, executive compensation arrangements, employment agreements, stock incentive plan matters, and stockholders agreement provisions, including transfer restrictions and ownership-guideline-related terms. The filing record also includes director transitions and governance disclosures connected to compensation, nominating and corporate governance, and clinical quality and compliance oversight.
RODGERS STEVEN E reported acquisition or exercise transactions in a Form 4 filing for AVAH. The filing lists transactions totaling 18,916 shares. Following the reported transactions, holdings were 312,414 shares.
Perchik Jerry reported acquisition or exercise transactions in a Form 4 filing for AVAH. The filing lists transactions totaling 49,653 shares. Following the reported transactions, holdings were 440,530 shares.
GANZI VICTOR F reported acquisition or exercise transactions in this Form 4 filing.
Aveanna Healthcare director Victor F. Ganzi reported an equity award of 18,916 common shares through a stock-settled restricted stock unit grant. The grant was made at a price of $0 per share and is subject to one-year cliff vesting. Following this award, Ganzi directly beneficially owns 502,522 shares of Aveanna Healthcare common stock.
An affiliated holder of AVAH common stock plans to sell 171,750 shares, with an aggregate market value of 1,361,978.00, through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 02/19/2026.
The securities relate to restricted stock vesting on 02/14/2026, when 425,304 shares of common stock were acquired from the issuer. Over the prior three months, the same account sold 50,970 shares of common stock for gross proceeds of 413,942.66.
Avah Holdings has a planned sale of 31,600 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ. The shares have an aggregate market value of $250,588.00, and the filing lists 251,676 shares of this class outstanding.
The securities to be sold were acquired on 02/14/2026 through restricted stock vesting from the issuer, totaling 89,788 shares on that date. The filing also notes a prior sale on 01/02/2026 of 34,607 shares of common stock for gross proceeds of $281,053.83.
AVAH filed a Rule 144 notice covering the planned sale of 489,500 shares of common stock, with an aggregate market value of $3,881,735.00, through Morgan Stanley Smith Barney on the NASDAQ around 02/19/2026.
The shares to be sold relate to a larger block of 978,851 common shares acquired from the issuer via restricted stock vesting on 02/14/2026. In the prior three months, the same account sold 84,960 shares of common stock on 01/02/2026 for gross proceeds of $689,985.65.
An affiliate of AVAH filed a Rule 144 notice to sell 52,100 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $413,153.00, on or around February 19, 2026 on NASDAQ.
The notice reports that these shares come from restricted stock vesting on February 14, 2026, when 136,204 shares of common stock were acquired from the issuer. It also discloses a prior sale of 36,015 shares of common stock in the past three months, generating $292,488.62 in gross proceeds. The filing states that the person relying on Rule 144 does not know of any undisclosed material adverse information about the issuer.
An insider of AVAH filed a notice of proposed sale of 38,000 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of 301,340.00. The filing lists 436,980 shares of this class outstanding.
The shares to be sold come from a larger block of 108,963 restricted shares that vested on 02/14/2026, acquired directly from the issuer. The same selling account disposed of 53,077 shares in the past three months for gross proceeds of 431,054.24. The seller affirms they are not aware of any undisclosed material adverse information about the issuer.
Aveanna Healthcare Holdings Inc. (AVAH) received an updated ownership report on a Schedule 13G/A. Several J.H. Whitney–affiliated entities disclosed beneficial ownership of Aveanna common stock as of 12/31/2025.
PSA Healthcare Investment Holding LLC reported beneficial ownership of 15,523,810 shares, or 7.43% of the common stock. J.H. Whitney VII, L.P. reported 19,292,787 shares, or 9.23%. PSA Iliad Holdings LLC reported 1,426,034 shares (0.68%), JHW Iliad Holdings LLC reported 3,460,515 shares (1.66%), and JHW Iliad Holdings II LLC reported 362,746 shares (0.17%).
Each reporting person has sole voting and dispositive power over its reported shares and no shared power. The J.H. Whitney entities and funds and entities advised by Bain Capital Investors, LLC are parties to a stockholders’ agreement to coordinate voting for director nominees and transfers of Aveanna common stock. Based on available information, that broader group may be deemed to beneficially own about 121,666,770 shares, or 58.24% of Aveanna’s common stock under applicable rules, though the J.H. Whitney parties expressly disclaim beneficial ownership of shares held by others.
Aveanna Healthcare Holdings Inc. filed a current report describing new financial outlook information. On January 14, 2026, the company issued a press release updating its full year guidance for fiscal 2025 and announcing its full year guidance for fiscal 2026. The guidance details are contained in a press release furnished as Exhibit 99.1 and a January 2026 investor presentation furnished as Exhibit 99.2. These materials are provided for informational purposes under Items 2.02 and 7.01 and are treated as “furnished,” not “filed,” under securities laws.